{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:27:43Z","timestamp":1787725663844,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychosomatics"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.psym.2014.08.001","type":"journal-article","created":{"date-parts":[[2014,8,8]],"date-time":"2014-08-08T15:49:19Z","timestamp":1407512959000},"page":"98-102","source":"Crossref","is-referenced-by-count":6,"title":["Depersonalization\/Derealization Disorder After Exposure to Mefloquine"],"prefix":"10.1016","volume":"56","author":[{"given":"Katherine","family":"McEvoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret S.","family":"Chisolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psym.2014.08.001_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1192\/bjp.182.5.428","article-title":"Depersonalisation disorder: clinical features of 204 cases","volume":"182","author":"Baker","year":"2003","journal-title":"Br J Psychiatry"},{"issue":"9","key":"10.1016\/j.psym.2014.08.001_bib2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4088\/JCP.v64n0903","article-title":"Feeling unreal: a depersonalization disorder update of 117 cases","volume":"64","author":"Simeon","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"20","key":"10.1016\/j.psym.2014.08.001_bib3","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1001\/archinte.1994.00420200116012","article-title":"Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine","volume":"154","author":"Hennequin","year":"1994","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.psym.2014.08.001_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PAF.0b013e3181f9443c","article-title":"Suicide by skull stab wounds: a case of drug-induced psychosis","volume":"31","author":"Jousset","year":"2010","journal-title":"Am J Forensic Med Pathol"},{"issue":"11","key":"10.1016\/j.psym.2014.08.001_bib5","first-page":"1606","article-title":"Case study: neuropsychiatric symptoms associated with the antimalarial agent mefloquine","volume":"36","author":"Clattenburg","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8997","key":"10.1016\/j.psym.2014.08.001_bib6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(96)90500-0","article-title":"Neuropsychiatric reactions with mefloquine chemoprophylaxis","volume":"347","author":"Croft","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.psym.2014.08.001_bib7","unstructured":"Food and Drug Administration: FDA drug safety communication: FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects. 2014. Updated July 29, 2013."},{"key":"10.1016\/j.psym.2014.08.001_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1192\/apt.11.2.92","article-title":"Understanding and treating depersonalisation disorder","volume":"11","author":"Medford","year":"2005","journal-title":"Adv Psychiatr Treat"},{"issue":"1-3","key":"10.1016\/j.psym.2014.08.001_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jad.2010.02.108","article-title":"Type-D personality and depersonalization are associated with suicidal ideation in the German general population aged 35-74: results from the Gutenberg heart study","volume":"125","author":"Michal","year":"2010","journal-title":"J Affect Disord"},{"issue":"12","key":"10.1016\/j.psym.2014.08.001_bib10","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1002\/da.20923","article-title":"Dissociative disorders in DSM-5","volume":"28","author":"Spiegel","year":"2011","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.psym.2014.08.001_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev-clinpsy-050212-185531","article-title":"Dissociative disorders in DSM-5","volume":"9","author":"Spiegel","year":"2013","journal-title":"Annu Rev Clin Psychol"},{"issue":"6","key":"10.1016\/j.psym.2014.08.001_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00023210-200418060-00002","article-title":"Depersonalisation disorder: a contemporary overview","volume":"18","author":"Simeon","year":"2004","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.psym.2014.08.001_bib13","first-page":"263","article-title":"The efficacy of lamotrigine in a resistant case of depersonalization disorder","volume":"39","author":"Rosagro-Escamez","year":"2011","journal-title":"Actas Esp Psiquiatr"},{"issue":"4","key":"10.1016\/j.psym.2014.08.001_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.rbp.2012.04.006","article-title":"Depersonalization and derealization syndrome: report on a case study and pharmacological management","volume":"34","author":"Salgado","year":"2012","journal-title":"Rev Bras Psiquiatr"},{"issue":"5","key":"10.1016\/j.psym.2014.08.001_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.WNF.0000228368.17970.DA","article-title":"Lamotrigine as an add-on treatment for depersonalization disorder: a retrospective study of 32 cases","volume":"29","author":"Sierra","year":"2006","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"10.1016\/j.psym.2014.08.001_bib16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4088\/JCP.v62n1012b","article-title":"Lamotrigine in the treatment of depersonalization disorder","volume":"62","author":"Sierra","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psym.2014.08.001_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/0269881103017001712","article-title":"A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder","volume":"17","author":"Sierra","year":"2003","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.psym.2014.08.001_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1192\/bjp.185.1.31","article-title":"Fluoxetine therapy in depersonalisation disorder: randomised controlled trial","volume":"185","author":"Simeon","year":"2004","journal-title":"Br J Psychiatry"},{"issue":"1","key":"10.1016\/j.psym.2014.08.001_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JCP.0b013e31820428e1","article-title":"Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity: randomized, double-blind, placebo-controlled study","volume":"31","author":"Aliyev","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psym.2014.08.001_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.jcp.0000162803.61700.4f","article-title":"An open trial of naltrexone in the treatment of depersonalization disorder","volume":"25","author":"Simeon","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psym.2014.08.001_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.brs.2013.07.006","article-title":"Effects of repetitive transcranial magnetic stimulation (rTMS) on specific symptom clusters in depersonalization disorder (DPD)","volume":"7","author":"Christopeit","year":"2014","journal-title":"Brain Stimulation"},{"key":"10.1016\/j.psym.2014.08.001_bib22","unstructured":"Food and Drug Administration: FDA approved drug products. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm. 2014. Accessed July 30, 2014."},{"issue":"2","key":"10.1016\/j.psym.2014.08.001_bib23","first-page":"224","article-title":"Psychiatric side effects of mefloquine: applications to forensic psychiatry","volume":"41","author":"Ritchie","year":"2013","journal-title":"J Am Acad Psychiatry Law"},{"issue":"4","key":"10.1016\/j.psym.2014.08.001_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.clpt.2006.07.003","article-title":"MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine","volume":"80","author":"Aarnoudse","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"10.1016\/j.psym.2014.08.001_bib25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1056\/NEJMct0709050","article-title":"Artesunate for the treatment of severe falciparum malaria","volume":"358","author":"Rosenthal","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Psychosomatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318214001297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318214001297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T22:51:03Z","timestamp":1538347863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318214001297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0033318214001297"],"URL":"https:\/\/doi.org\/10.1016\/j.psym.2014.08.001","relation":{},"ISSN":["0033-3182"],"issn-type":[{"value":"0033-3182","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}